# Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

> **NCT01355393** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 50 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Male Breast Cancer
- Recurrent Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **BIOLOGICAL:** HER-2/neu peptide vaccine
- **BIOLOGICAL:** sargramostim
- **DRUG:** rintatolimod

## Key facts

- **NCT ID:** NCT01355393
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2013-11
- **Final completion:** —
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01355393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01355393, "Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01355393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*